Lupin gets ISO 14001 and ISO 45001 certification across all its Indian manufacturing sites, RnD Center, Corporate Office

Published On 2024-05-16 06:45 GMT   |   Update On 2024-05-16 06:45 GMT
Advertisement

Mumbai: Global pharma major Lupin Limited has announced that all 12 of its manufacturing sites, its R&D Center and corporate office in India have successfully completed rigorous audits and been certified by DNV for ISO 14001 — Environment Management Systems (EMS), and ISO 45001 — Occupational Health and Safety Management System (OHSMS).

ISO 14001 is an internationally recognized standard for Environmental Management Systems.

Advertisement

"This certification demonstrates Lupin’s dedication to minimizing its environmental footprint and fostering sustainable practices across its operations. The ISO 45001 certification underscores Lupin’s unwavering commitment to ensuring the health, safety and well-being of its employees and stakeholders," the release stated.

Commenting on this remarkable achievement, Nilesh Gupta, Managing Director, Lupin, said, “We are very proud of this achievement; it acknowledges our steadfast commitment to excellence in environmental stewardship and workplace safety and is a reflection of our ongoing efforts to integrate sustainable practices into our business operations and prioritize the health and safety of our people.”

Read also: Lupin ropes in Jeffrey Kindler, Alfonso Zulueta as Independent Directors

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas.

Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24. Lupin has 15 manufacturing sites, 7 research centers.

Read also: Lupin ropes in Jeffrey Kindler, Alfonso Zulueta as Independent Directors

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News